Biomedical subjects
C J Oon
Publications and source records attributed to C J Oon.
Clinical applications of the continuous flow blood separator machine.
The NCl/IBM or Aminco Continuous Flow Blood Separator Machine is a safe apparatus for the selective removal or exchange of either packed red blood cells, leucocyte-rich or platelet-rich layers or plasma. Abnormal fractions from any of these layers may be collected and discarded. Normal constituents may be collected for therapeutic uses. The wide scope of its applications includes important uses in clinical immunology: temporary provision of good leucocytes or platelets; harvesting of immune leucocytes (preparation of transfer factor at up to 10 units per harvest); removal of cryo- or macro-globulins, immune complexes or blocking factors; replacement therapy for antibody or complement deficiencies. Examples are given of such uses together with some of the medical problems so far encountered.
Sézary syndrome: treatment by leukophoresis.
Explore the source record for details and available documents.
T-lymphocyte responses in patients with malignant melanoma.
Explore the source record for details and available documents.
Excess IgD bearing lymphocytes in patients with malignant melanoma.
B lymphocytes from the peripheral blood of 15 melanoma patients and 14 normal adults were studied using immunofluorescence to IgA, IgG, IgD and IgM surface markers. The total number of peripheral blood B lymphocytes was increased in the melanoma patients (1048/mm(3)) compared with normal controls (504) (P<0·01).The expression of excess IgD bearing lymphocytes in these melanoma patients may reflect a derepression of oncofoetal type.
Immunogenicity and safety of low doses of recombinant yeast-derived hepatitis B vaccine.
The immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine given in doses of 0.6 microgram, 1.25 microgram, 2.5 micrograms and 5.0 micrograms were studied in 4 comparable groups of children aged 1-12 years. All children received three doses of vaccine at time 0, 1 month and 5 months. Immunogenicity appeared to be satisfactory in all 4 groups of children. In the early phase of the study, a dose-response relationship was observed but there was no significant difference in the geometric mean titre among all 4 groups for any period studied. Antibody levels peaked at 9 months, declining thereafter. The geometric mean titre one year after the first vaccine dose was not significantly lower than that at the peak (9 months) in any individual group studied. The second year geometric mean titre was similar in all 4 groups and lower than that of the first year. Sero-conversion with antibody titres greater than or equal to 10 mIU/ml was 100% in the 5.0 micrograms group and greater than 90% in the other 3 groups. There were no adverse reactions of any significance. The immunogenicity of recombinant yeast-derived hepatitis B vaccine was found to be adequate even at as low a dosage as 0.6 microgram when administered in a 3-dose regimen.